TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04635072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stabilised Whole Rice Bran
Description: Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
Study: NCT01407497

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA HIVIS and MVA-CMDR
Description: 600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA HIVIS and MVA-CMDR
Description: 1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
Study: NCT02012608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Oral glutamine for subjects undergoing breast conserving therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects undergoing breast conserving therapy
Study: NCT01718509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 50 or 70 mg administered orally, once-daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once-daily, orally, for up to 12 weeks
Study: NCT02004912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentoring intervention
Description: The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
Study: NCT03075176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized LASIK
Description: Wavefront optimized laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized LASIK
Description: Wavefront optimized laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized Photorefractive Keratectomy
Description: Wavefront optimized laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized Photorefractive Keratectomy
Description: Wavefront optimized laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided LASIK
Description: Topography-guided laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided LASIK
Description: Topography-guided laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided Photorefractive Keratectomy
Description: Topography-guided laser vision correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography-guided Photorefractive Keratectomy
Description: Topography-guided laser vision correction
Study: NCT00129805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-9042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT01131624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate
Description: 200 mg iron per day in a convenient dosage schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: 1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
Study: NCT02808338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips BiPAP AutoSV Advanced System One
Description: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Philips BiPAP ASV
Description: This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S7 VPAP Adapt
Description: This device is FDA approved and will be set to predetermined setting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S9 VPAP Adapt
Description: This device is FDA approved and will be set to predetermined setting.
Study: NCT02287324

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Contact
Study: NCT02658565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
Study: NCT05344144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
Study: NCT01044238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: 18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: 18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
Study: NCT02864940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossword puzzle
Description: This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
Study: NCT00370695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulation System
Description: Stimulation turned on from implant throughout the Study
Study: NCT01258101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks
Study: NCT03126487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY FOCUSED ULTRASOUND
Description: HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
Study: NCT05951426

Intervention type: PROCEDURE
Intervention: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Description: 1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium

Intervention type: PROCEDURE
Intervention: 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
Description: 1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium
Study: NCT02983409

Intervention type: RADIATION
Intervention: Pstone
Description: A adult patients who were diagnosed as urinary stone by the urinary CT
Study: NCT00600340

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and Paclitaxel
Description: A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and Capecitabine
Description: B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
Study: NCT04798677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABBC1 Immunoessential
Description: Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABBC1 Immunoessential
Description: Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for dissolution in water, excipents. Lemon flavor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for dissolution in water, excipents. Lemon flavor
Study: NCT01602484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-prepared Splint Pack composed by Medline
Description: Applying splint by using pre-prepared splint pack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk splint supplies
Description: Applying splint by using the bulk splint supplies
Study: NCT03551093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISS SPG stimulation
Description: The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
Study: NCT04754464

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
Study: NCT02697357

Intervention type: BEHAVIORAL
Intervention: Psychosocial Instruments

Intervention type: BEHAVIORAL
Intervention: Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
Study: NCT04600284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg
Study: NCT03025217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Lifestyle Coaching (TLC)
Study: NCT03054467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caduet 10Mg-20Mg Tablet
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NorvasC® 10 mg Tablets
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Study: NCT03864718

Intervention type: PROCEDURE
Intervention: photodynamic therapy
Description: Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
Study: NCT01953536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide 2.5 mg
Description: During treatment, participants receive IV vintafolide 2.5 mg.
Study: NCT04600284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2101
Description: AD-2101 16/5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2102
Description: AD-2102 25mg
Study: NCT01953536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide 2.5 mg
Description: During treatment, participants receive IV vintafolide 2.5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel 80 mg/m^2
Description: During treatment, participants receive IV paclitaxel 80 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m^2
Description: During treatment, participants receive IV paclitaxel 80 mg/m\^2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etarfolatide
Description: During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide
Description: During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide
Description: During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
Study: NCT01258101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 800 mg orally daily
Study: NCT01953536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication for Paclitaxel
Description: During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premedication for Paclitaxel
Description: During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
Study: NCT03810417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin Antibodies Fab Fragments
Description: Digoxin antibodies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06156514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
Study: NCT02645383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PASCAL laser
Description: A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laser
Description: Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
Study: NCT01415037

Intervention type: PROCEDURE
Intervention: annular array ultrasound exam
Description: For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
Study: NCT03039127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Description: Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
Study: NCT00242580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin photodynamic therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy
Description: After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study: NCT05237921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Dietary Intervention (CEDI)
Description: Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard Care
Study: NCT04600284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2102
Description: AD-2102 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2102
Description: AD-2102 25mg
Study: NCT01258101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 800 mg orally daily
Study: NCT04600284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2102
Description: AD-2102 25mg
Study: NCT01258101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 400 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 400 mg orally daily
Study: NCT00747292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural
Description: Patients in this limb receive epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Patients in this limb receive a PCA for their pain control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal
Description: Patients in limb will receive spinal analgesia
Study: NCT01640184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroidectomy
Description: sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active vitamin D
Description: CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation
Description: CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.